Quadrant Capital Group’s Aclaris Therapeutics ACRS Stock Holding History

Quadrant Capital Group’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-365	Closed	-$2.5K	–	2692
2023 Q3	$2.5K	Buy	365 +312	+589%	+$2.67K	﹤0.01%	2330
2023 Q2	$550	Sell	53 -15	-22%	-$136	﹤0.01%	2558
2023 Q1	$551	Buy	+68	New	+$863	﹤0.01%	2598
2022 Q3	–	Sell	-84	Closed	-$1K	–	2619
2022 Q2	$1K	Hold	84	–	–	﹤0.01%	2311
2022 Q1	$1K	Buy	+84	New	+$1.15K	﹤0.01%	2230

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Quadrant Capital Group's ACRS Position: Q4 2023 in Review

Quadrant Capital Group sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 365 shares — an estimated $2.5K sold.

Quadrant Capital Group first reported a position in ACRS in Q1 2022 and held it in 5 quarters. The position peaked at $2.5K in Q3 2023. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Quadrant Capital Group reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Quadrant Capital Group sold 365 Aclaris Therapeutics shares in Q4 2023, an estimated $2.5K.
Quadrant Capital Group first reported a position in Aclaris Therapeutics in Q1 2022 and held it in 5 quarters.
Quadrant Capital Group's Aclaris Therapeutics position peaked at $2.5K in Q3 2023.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Quadrant Capital Group's 13F filing for Q4 2023, filed 8 Feb 2024.